| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18748 R79716 |
Moore (Pregabalin) (Epilepsy) (Controls exposed to LTG), 2025 | Congenital conditions (any major structural congenital condition with no known associated/underlying genetic condition, as defined by EUROCAT) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
2.06 [0.67;6.35] C excluded (control group) |
4/68 16/543 | 20 | 68 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18747 R79713 |
Moore (Pregabalin) (Epilepsy) (Controls unexposed, sick), 2025 | Congenital conditions (any major structural congenital condition with no known associated/underlying genetic condition, as defined by EUROCAT) | during pregnancy (anytime or not specified) excluded | population based cohort retrospective | unexposed, sick | Adjustment: No Matched |
5.13 [1.49;17.70] excluded (exposition period) |
4/68 8/667 | 12 | 68 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18715 R79623 |
The NAAED (Pregabalin) (Epilepsy), 2025 | Major congenital malformations | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 5.22 [0.28;98.62] C | 0/5 40/1,944 | 40 | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S16713 R70303 |
Battino, 2024 | Major congenital malformations (MCMs) | early pregnancy | prospective cohort | exposed to other treatment, sick | Adjustment: No | 2.42 [0.14;43.19] C | 0/7 110/3,584 | 110 | 7 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7796 R23014 |
Vajda (Pregabalin) (Controls exposed to Lamotrigine, sick), 2019 | Fetal malformations | at least 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
18.80 [0.36;971.86] C excluded (control group) |
0/1 20/406 | 20 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7797 R23015 |
Vajda (Pregabalin) (Controls unexposed, sick), 2019 | Fetal malformations | at least 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 31.00 [0.56;1711.11] C | 0/1 5/176 | 5 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 3 studies | 5.55 [0.89;34.62] | 155 | 13 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Pregabalin) (Epilepsy; 2: Pregabalin) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 7796, 18748